MNPR-101 RIT (Radio-immuno-therapeutic)

Patent applications have been filed with the U.S. Patent and Trademark Office covering the use of uPAR-targeted RITs for the treatment of severe COVID-19 and a composition of matter patent covering MNPR-101-PCTA-Ac²²⁵.

MNPR-101 (formerly huATN-658)

Monopar's patent portfolio for MNPR-101, as well as its epitope, consists of two issued U.S. composition of matter and their method of use patents, and allowed patent applications and corresponding (granted and pending) patents and patent applications in 22 foreign jurisdictions, including the European Union, Japan, and other Asian countries.